The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Xeris Biopharma Holdings Inc shares valued at $176,257 were sold by Shannon John Patrick Jr on Jan 05 ’26. At $7.08 per share, Shannon John Patrick Jr sold 24,907 shares. The insider’s holdings dropped to 2,705,346 shares worth approximately $19.51 million following the completion of this transaction.
Also, Hecht Beth sold 16,667 shares, netting a total of over 123,776 in proceeds. Following the sale of shares at $7.43 each, the insider now holds 1,308,103 shares.
Before that, JOHN H JOHNSON had added 135,402 shares to its account. In a trade valued at $977,034, the Director bought Xeris Biopharma Holdings Inc shares for $7.22 each.
As published in their initiating research note from Barclays on December 09, 2025, Xeris Biopharma Holdings Inc [XERS] has been an Overweight and the price target has been revised to $9. As of November 11, 2024, Piper Sandler has decreased its “an Overweight” rating to a “Neutral” for XERS. Earlier on March 28, 2024, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for XERS stock.
Analyzing XERS Stock Performance
On last trading session, Xeris Biopharma Holdings Inc [NASDAQ: XERS] rose 3.59% to $7.21. The stock’s lowest price that day was $6.96, but it reached a high of $7.365 in the same session. During the last five days, there has been a drop of approximately -1.37%. Over the course of the year, Xeris Biopharma Holdings Inc shares have jumped approximately 99.72%. Shares of the company reached a 52-week high of $7.95 on 01/02/26 and a 52-week low of $6.88 on 01/05/26.
Support And Resistance Levels for Xeris Biopharma Holdings Inc (XERS)
According to the 24-hour chart, there is a support level at 6.99, which, if violated, would cause prices to drop to 6.77. In the upper region, resistance lies at 7.40. The next price resistance is at 7.58. RSI (Relative Strength Index) is 48.96 on the 14-day chart, showing neutral technical sentiment.
Is Xeris Biopharma Holdings Inc subject to short interest?
Stocks of Xeris Biopharma Holdings Inc saw a sharp steep in short interest on 2025-12-15 dropping by -0.31 million shares to 15.43 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 15.75 million shares. A decline of -2.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.55 of the overall float, the days-to-cover ratio (short ratio) decline to 7.55.
Which companies own the most shares of Xeris Biopharma Holdings Inc (XERS)?
In terms of Xeris Biopharma Holdings Inc share price expectations, FactSet research, analysts set an average price target of 13.5 in the next 12 months, up nearly 93.97% from the previous closing price of $6.96. Analysts anticipate Xeris Biopharma Holdings Inc stock to reach 18 by 2026, with the lowest price target being 9. In spite of this, 3 analysts ranked Xeris Biopharma Holdings Inc stock as Buy at the end of 2026. On August 28, 2023, Craig Hallum assigned a price target of “a Buy” to the stock and initiated coverage with a $4.50.
